Emcure Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Emcure Pharmaceuticals Limited
MNC (JVs and subsidiaries)
Industry Pharmaceutical
Founded 1983
Headquarters Hinjwadi, Pune, India
Key people

Satish Mehta

[1] CEO
Products tablets, capsules, softgels, injectables, Lyophilized sterile parenterals, Onco products
US$220 million
Number of employees
Website www.emcure.com

Emcure Pharmaceuticals headquartered at Pune in West India is an Indian pharmaceutical company. The company's legal products include tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.

Indian plants[edit]

  • Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets.
  • Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has lyophilization and pfs capability
  • Oncology injectable facility at Hinjawadi
  • Solid Orals facilities at Jammu and Bhosari
  • API facility at Kurkumbh- USFDA approved
  • Biotech facility at Hinjawadi
  • R&D center and upcoming plant at Ahmedabad

US plant[edit]

USA - The company has a manufacturing facility and R&D center at East Brunswick, New Jersey, USA.

Capital markets[edit]

Emcure is planning to raise money through an initial public offering for some time now [2] In 2014, Blackstone sold its stake in Emcure to Bain Capital [3]


There have been many cases of recalls announced by Pharma majors like Pfizer & Teva after having manufactured their products with their partner Emcure. In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Bacillus Anthracis, Penicillium Chrysogenum & E coli in some samples.[4] Teva recalled several batches of two products due to white tablets showing presence of Yersinia Pestis in 2011.[5]

AIDS Initiative[edit]

Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility (which all of the public knows is just lofty words thinly disguissed as altruistic concern)it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.

Emcure has license agreements with Bristol-Myers Squibb for Atazanavir [6] and Gilead Sciences for Tenofovir [7] as part of their Global Access Programs.

Anticancer portfolio[edit]

Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India.[8] Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.[9] The monthly doses priced at around $30 million are expected to be raised significantly for lesser access to cancer therapy.


External links[edit]